AC
CPRX

AXQ Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

AXQ Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$331K Sell
10,538
-7,954
-43% -$235K 0.04% 587
2026
Q1 		$458K Buy
18,492
+1,120
+6% +$26.7K 0.06% 440
2025
Q4 		$405K Buy
+17,372
New +$387K 0.09% 340

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AXQ Capital's CPRX Position: Q2 2026 in Review

AXQ Capital reduced its Catalyst Pharmaceutical (CPRX) stake by 43% in Q2 2026, selling an estimated $235K and leaving 10,538 shares worth $331K. The position accounts for 0.04% of the portfolio, ranked #587.

AXQ Capital first reported a position in CPRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $458K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • AXQ Capital held 10,538 shares of Catalyst Pharmaceutical worth $331K as of Q2 2026.
  • AXQ Capital sold 7,954 Catalyst Pharmaceutical shares in Q2 2026, an estimated $235K.
  • Catalyst Pharmaceutical made up 0.04% of AXQ Capital's portfolio in Q2 2026, its #587 holding.
  • AXQ Capital first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • AXQ Capital's Catalyst Pharmaceutical position peaked at $458K in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.